Okay. Deep breath. Earendil Labs just raised $787 million. Seven hundred and eighty-seven million dollars. For an AI-driven biologics company that most people in Western biotech circles haven’t even heard of yet. The round includes Sanofi, a Biotech Development Fund co-created by Hillhouse and Pfizer, DST Global, Dimension Capital, INCE Capital, Luminous Ventures, and Miracle Capital.

That number alone would make this noteworthy. But the funding is just the latest signal in what’s rapidly becoming one of the most consequential AI-in-biotech stories of 2026.

Let me lay out the timeline. In April 2025, Sanofi signed a $125 million deal with Earendil for exclusive worldwide rights to two bispecific antibodies. By January 2026, Sanofi came back for seconds — a $160 million near-term deal expanding the partnership to multiple autoimmune and inflammatory disease programs, with total deal value reaching $2.56 billion including milestones and royalties. In February, Earendil signed a manufacturing partnership with WuXi Biologics for bispecific/multispecific antibodies and ADCs. Then in March, another WuXi collaboration — this time with WuXi XDC on their payload-linker platform. And now, $787M in fresh capital.

And they already have a clinical asset. HXN-1001, a half-life extended anti-TL1A monoclonal antibody, is in Phase 2 for ulcerative colitis and Crohn’s disease. TL1A is one of the hottest targets in inflammatory bowel disease right now — Merck paid $10.8 billion for Prometheus Biosciences largely on the strength of its TL1A inhibitor. Earendil is in that race with an AI-designed candidate that’s already in patients.

The platform itself combines what the company describes as advanced predictive protein modeling with high-throughput experimental validation. Think of it as a closed-loop system: AI generates candidate biologics, the lab tests them, and the data feeds back into the model. The output isn’t just antibodies — it’s bispecifics, multispecifics, and ADCs. The breadth of the WuXi manufacturing deals tells you they’re not dabbling — they’re building a full modality stack.

When Sanofi comes back twice in under a year with escalating deal sizes… when Pfizer creates a dedicated fund to back you… when you raise nearly $800M in a single round… the market is telling you something. Earendil Labs may be the most significant AI-native biologics company you’ve never heard of. That won’t last long.